ABSTRACT NUMBER: ESOC2026A1065 ACUTE ISCHEMIC STROKE OUTCOMES WITH EDARAVONE–DEXBORNEOL: A META-ANALYTIC STUDY
Himanshu Sharma, K H Reeta · 2026
Read ABSTRACT NUMBER: ESOC2026A1065 ACUTE ISCHEMIC STROKE OUTCOMES WITH EDARAVONE–DEXBORNEOL: A META-ANALYTIC STUDY by Himanshu Sharma, K H Reeta (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13145558.txt.
Description
Himanshu Sharma and K H Reeta pool the trials of a brain-protecting drug pair for acute ischemic stroke. Edaravone dexborneol fights oxidation and inflammation, two forces that widen stroke damage. Searching two databases to November 2025, the pair found four randomized trials covering 2,268 patients. The main test was whether patients reached functional independence, a score of one or less on the standard disability scale, at 90 days.
The drug pair raised the odds of that good outcome by 46 percent against control treatment, with no variation across trials. The benefit held in patients who got clot treatment, in the elderly, and in those with worse strokes. Serious side effects and deaths did not rise. Three trials carried low bias risk and one raised some concerns. The authors back the drug as a broad add-on for stroke care.
Catalog record
| CREATOR | Himanshu Sharma, K H Reeta |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |